CD274 and non-small cell lung carcinoma: Ikeda et al. (2021) longitudinally evaluated the PD-L1 positivity rate in CTCs, from advanced NSCLC patients isolated by the MCA system, at baseline (82%) and after 4, 8, 12, and 24 weeks, following nivolumab treatment, with rates of 58%, 56%, 62%, and 55%, respectively [41].